RESUMEN
UNLABELLED: Microvascular invasion (MVI) in hepatocellular carcinoma (HCC) is an independent predictor of poor outcomes subsequent to surgical resection or liver transplantation (LT); however, MVI currently cannot be adequately determined preoperatively. Radiogenomic venous invasion (RVI) is a contrast-enhanced computed tomography (CECT) biomarker of MVI derived from a 91-gene HCC "venous invasion" gene expression signature. Preoperative CECTs of 157 HCC patients who underwent surgical resection (N = 72) or LT (N = 85) between 2000 and 2009 at three institutions were evaluated for the presence or absence of RVI. RVI was assessed for its ability to predict MVI and outcomes. Interobserver agreement for scoring RVI was substantial among five radiologists (κ = 0.705; P < 0.001). The diagnostic accuracy, sensitivity, and specificity of RVI in predicting MVI was 89%, 76%, and 94%, respectively. Positive RVI score was associated with lower overall survival (OS) than negative RVI score in the overall cohort (P < 0.001; 48 vs. >147 months), American Joint Committee on Cancer tumor-node-metastasis stage II (P < 0.001; 34 vs. >147 months), and in LT patients within Milan criteria (P < 0.001; 69 vs. >147 months). Positive RVI score also portended lower recurrence-free survival at 3 years versus negative RVI score (P = 0.001; 27% vs. 62%). CONCLUSION: RVI is a noninvasive radiogenomic biomarker that accurately predicts histological MVI in HCC surgical candidates. Its presence on preoperative CECT is associated with early disease recurrence and poor OS and may be useful for identifying patients less likely to derive a durable benefit from surgical treatment.
Asunto(s)
Biomarcadores de Tumor/análisis , Carcinoma Hepatocelular/diagnóstico por imagen , Carcinoma Hepatocelular/mortalidad , Neoplasias Hepáticas/diagnóstico por imagen , Neoplasias Hepáticas/mortalidad , Células Neoplásicas Circulantes/patología , Intensificación de Imagen Radiográfica/métodos , Análisis de Varianza , California , Carcinoma Hepatocelular/patología , Carcinoma Hepatocelular/cirugía , Estudios de Cohortes , Estudios Transversales , Supervivencia sin Enfermedad , Femenino , Hepatectomía/métodos , Hepatectomía/mortalidad , Humanos , Neoplasias Hepáticas/patología , Neoplasias Hepáticas/cirugía , Trasplante de Hígado , Masculino , Microvasos/patología , Persona de Mediana Edad , Análisis Multivariante , Invasividad Neoplásica/patología , Recurrencia Local de Neoplasia/mortalidad , Recurrencia Local de Neoplasia/patología , Estadificación de Neoplasias , Cuidados Preoperatorios/métodos , Pronóstico , Modelos de Riesgos Proporcionales , Estudios Prospectivos , Radiofármacos , Estadísticas no Paramétricas , Análisis de Supervivencia , Tomografía Computarizada por Rayos X/métodos , Resultado del TratamientoRESUMEN
PURPOSE: To evaluate the efficacy of an ultralow-porosity expanded polytetrafluoroethylene (ePTFE) covered stent in the treatment of autogenous arteriovenous fistula (AVF) and prosthetic arteriovenous graft (AVG) venous outflow stenoses. MATERIALS AND METHODS: Clinical and angiographic outcomes of 20 consecutive patients with arteriovenous dialysis circuits treated with the endoprosthesis were reviewed following institutional review board approval. Patients were followed routinely at 2 months and 6 months after stent placement, or earlier if clinically warranted. The primary endpoint was 2- and 6-month primary treatment area patency. Secondary endpoints included primary circuit patency, primary assisted patency, and secondary patency. RESULTS: Eleven patients with AVFs and nine patients with AVGs were treated successfully with the covered stent. Primary treatment area patency rates were 85% ± 16 at both 2 months and 6 months. Primary circuit patency rates were was 65% ± 21 and 45% ± 22, respectively; primary assisted patency rates were 90% ± 13 and 85% ± 16, respectively; and secondary patency rates were 100% and 90% ± 13, respectively. Of the three cases of lost primary treatment area patency, two developed thrombosis and one developed recurrent stenosis. No significant differences were found between patients with AVFs and AVGs. CONCLUSIONS: Data from this preliminary study suggests that the ultralow-porosity ePTFE covered stent may be a clinically viable option for treatment of venous outflow stenoses in arteriovenous vascular access circuits.
Asunto(s)
Angioplastia de Balón/instrumentación , Derivación Arteriovenosa Quirúrgica/efectos adversos , Implantación de Prótesis Vascular/efectos adversos , Implantación de Prótesis Vascular/instrumentación , Prótesis Vascular , Oclusión de Injerto Vascular/terapia , Politetrafluoroetileno , Diálisis Renal , Stents , Grado de Desobstrucción Vascular , Adulto , Anciano , Angioplastia de Balón/efectos adversos , Femenino , Oclusión de Injerto Vascular/diagnóstico , Oclusión de Injerto Vascular/etiología , Oclusión de Injerto Vascular/fisiopatología , Humanos , Estimación de Kaplan-Meier , Masculino , Persona de Mediana Edad , Porosidad , Diseño de Prótesis , Recurrencia , Trombosis/etiología , Trombosis/terapia , Factores de Tiempo , Resultado del TratamientoRESUMEN
OBJECTIVE: The purpose of this study was to retrospectively assess the potential benefits of delayed phase imaging series in routine CT scans of the abdomen and pelvis. MATERIALS AND METHODS: Routine contrast-enhanced abdominopelvic CT scans of 1000 consecutively examined patients (912 men, 88 women; average age, 60 years; range, 22-94 years) were retrospectively evaluated, and the added benefits of the delayed phase series through the abdomen were recorded for each examination. Examinations performed for indications requiring multiphasic imaging were excluded. Images were reviewed by two fellowship-trained abdominal radiologists, who were blinded to official CT reports. All examinations were performed between July 2008 and February 2010 at a single institution. Radiation doses for both the portal venous and delayed phases, when available, were analyzed to assess the effect of the delayed phase on overall radiation exposure. RESULTS: Forty-two patients (4.2%) had findings that were further characterized or were observed only in the delayed phase. Most were incidental findings that could have been confirmed at noninvasive follow-up imaging, such as sonography or unenhanced CT or MRI. The most common findings were liver hemangioma (n = 12), adrenal adenoma (n = 12), and parapelvic renal cysts (n = 6). The most important finding was detection of a renal mass in one patient (0.1%). The mass was seen only on the delayed phase images but was difficult to appreciate in the portal venous phase. In the other 958 patients (95.8%), delayed imaging was of no benefit. In addition, use of the delayed phase resulted in a mean 59.5% increase in effective radiation dose. CONCLUSION: An additional delayed phase through the abdomen in routine contrast-enhanced CT examinations of the abdomen and pelvis is of low yield, particularly if reliable follow-up imaging to further elucidate uncertain findings is available.
Asunto(s)
Pelvis/diagnóstico por imagen , Dosis de Radiación , Radiografía Abdominal/estadística & datos numéricos , Tomografía Computarizada por Rayos X/estadística & datos numéricos , Adulto , Anciano , Anciano de 80 o más Años , Medios de Contraste , Femenino , Humanos , Hallazgos Incidentales , Yohexol , Masculino , Persona de Mediana Edad , Radiografía Abdominal/efectos adversos , Estudios Retrospectivos , Factores de Tiempo , Tomografía Computarizada por Rayos X/efectos adversos , Ácidos TriyodobenzoicosRESUMEN
INTRODUCTION: Medication administration via intravenous push presents multiple potential advantages; however, there may be an increased risk of adverse drug reactions. In 2020, Brigham and Women's Hospital changed levetiracetam intravenous administration to intravenous push (IVP). OBJECTIVE: The purpose of this analysis was to compare the safety profile of IVP to intravenous piggyback (IVPB) levetiracetam administration. METHODS: This institutional review board-approved, single-center, pre-post analysis was performed between 1 November, 2019 and 30 May, 2020. The electronic health record was used to identify all administrations of intravenous levetiracetam greater than 1000 mg in patients ≥ 18 years old. The major safety outcomes included hypotension, bradycardia, drug-induced sedation, and intravenous site reactions such as phlebitis and infiltration. The major efficiency outcome was the time from pharmacy order verification to first-dose administration. RESULTS: A total of 498 administrations in 162 patients were included in the analysis: 252 administrations in 84 patients in the IVP group and 246 administrations in 78 patients in the IVPB group. The incidence of bradycardia was 7 vs 3 (3.2% vs 1.5%, p = 0.34); hypotension 10 vs 6 (5.2% vs 3.5%, p = 0.44); sedation 21 vs 36 (19.3% vs 27.9%, p = 0.12); and peripheral IV site reactions 0 vs 1 (0% vs 0.6%, p = 0.39) in the IVP vs IVPB groups, respectively. The median time between order verification and first-dose administration was significantly reduced in the IVP vs IVPB group (23.5 vs 55 min, p < 0.001). CONCLUSIONS: Intravenous push levetiracetam administration of doses up to 4000 mg was associated with a similar incidence of cardiovascular, sedation, and infusion site-related adverse events compared to IVPB and resulted in a significant reduction in time to first-dose administration. Intravenous push levetiracetam in doses as high as 4000 mg may be considered safe with appropriate monitoring.
Asunto(s)
Bradicardia , Hipotensión , Centros Médicos Académicos , Administración Intravenosa , Adolescente , Bradicardia/inducido químicamente , Bradicardia/epidemiología , Femenino , Humanos , Hipotensión/inducido químicamente , Hipotensión/epidemiología , Infusiones Intravenosas , Levetiracetam/efectos adversos , Estudios RetrospectivosRESUMEN
PURPOSE: To investigate the use of an expanded polytetrafluoroethylene-coated nitinol stent-graft in patients with failing hemodialysis access circuits and compare grafts with and without a heparin-coated surface. MATERIALS AND METHODS: A single-institution retrospective review of 16 patients (average age, 55 years; seven men) treated for hemodialysis access circuit stenoses was performed. Patients had a prosthetic arteriovenous (AV) graft (n = 10) or autogenous AV fistula (n = 6), all with clinically relevant access stenoses that were refractory to angioplasty alone; 10 patients also had access circuit thrombosis at the time of treatment. Stents were placed in the basilic (n = 4), brachial (n = 7), cephalic (n = 4), and femoral (n = 1) veins. Study endpoints included primary treatment area patency, primary circuit patency, primary assisted circuit patency, and secondary circuit patency, followed to a maximum of 6 months. RESULTS: Primary treatment area patency rates at 30 days and 180 days were 75% and 31%, respectively. Secondary patency rates at the same time points were 88% and 68%, respectively. Mean primary treatment area patency was 93 days. Thrombosis was a major cause of failure, occurring in seven of 11 cases of primary treatment area patency loss. Subgroup analysis demonstrated that the heparin-coated configuration (n = 7) showed a 6-month primary patency rate of 57%, compared with 11% for the stent-grafts without heparin bonding (n = 9; P = .06). CONCLUSIONS: Overall, the majority of deployed stent-grafts lost primary patency within 6 months, with thrombosis a major cause of failure. However, the addition of a heparin-coated surface appeared to improve results in these otherwise treatment-refractory access circuits.